Product
Help
Pricing
About
Jobs
Log in
Get started
Author
Add to collection
Andrew E. Denker
Observed names:
A Denker,
A. Denker,
A. E. Denker,
A.E. Denker,
AE Denker,
Andrew Denker,
Denker, Andrew
show all 7
Observed institutions:
Merck & Co., Inc., Rahway, NJ, USA (United States),
Thomas Jefferson University,
Alexion Pharmaceuticals (United States)
ORCID:
0000-0001-5929-2472
Observed ORCID:
0000-0001-5929-2472
OpenAlex ID:
A5006014530
Chondrogenic differentiation of murine C3H10T1/2 multipotential mesenchymal cells: I. Stimulation by bone morphogenetic protein-2 in high-density micromass cultures
1999
·
Andrew E. Denker
, Andrew R. Haas
, et al.
·
Differentiation
·
252
Formation of cartilage-like spheroids by micromass cultures of murine C3H10T1/2 cells upon treatment with transforming growth factor-β1
1995
·
Andrew E. Denker
, Steven B. Nicoll
, et al.
·
Differentiation
·
200
Odanacatib in the treatment of postmenopausal women with low bone mineral density: Five years of continued therapy in a phase 2 study
2012
·
Bente Langdahl
, Neil Binkley
, et al.
·
Journal of Bone and Mineral Research
·
158
Five-year efficacy and safety of asfotase alfa therapy for adults and adolescents with hypophosphatasia
2018
·
Priya S. Kishnani
, Cheryl Rockman-Greenberg
, et al.
·
Bone
·
151
PDF
The long-acting C5 inhibitor, ravulizumab, is effective and safe in pediatric patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment
2020
·
Gema Ariceta
, Bradley P. Dixon
, et al.
·
Kidney International
·
101
PDF
Pharmacokinetic Considerations in Determining the Terminal Elimination Half-Lives of Bisphosphonates
2005
·
Kenneth C Lasseter
, Arturo G Porras
, et al.
·
Clinical Drug Investigation
·
68
Single-Dose Pharmacokinetics and Tolerability of Alendronate 35- and 70-Milligram Tablets in Children and Adolescents with Osteogenesis Imperfecta Type I
2005
·
L. M. Ward
, A. E. Denker
, et al.
·
The Journal of Clinical Endocrinology & Metabolism
·
64
A Phase 2, Randomized, Placebo-Controlled, Dose-Ranging Study of the Calcium-Sensing Receptor Antagonist MK-5442 in the Treatment of Postmenopausal Women With Osteoporosis
2014
·
Johan Halse
, Susan Greenspan
, et al.
·
The Journal of Clinical Endocrinology & Metabolism
·
46
Efficacy and safety of the long-acting C5 inhibitor ravulizumab in patients with atypical hemolytic uremic syndrome triggered by pregnancy: a subgroup analysis
2021
·
Anja Gäckler
, Ulf Schönermarck
, et al.
·
BMC Nephrology
·
45
PDF
Pharmacodynamics of asfotase alfa in adults with pediatric-onset hypophosphatasia
2020
·
Lothar Seefried
, Priya S. Kishnani
, et al.
·
Bone
·
41
PDF
HA-1–targeted T-cell receptor T-cell therapy for recurrent leukemia after hematopoietic stem cell transplantation
2024
·
Elizabeth F. Krakow
, Michelle Brault
, et al.
·
Blood
·
38
A randomized phase II trial of ridaforolimus, dalotuzumab, and exemestane compared with ridaforolimus and exemestane in patients with advanced breast cancer
2017
·
Hope S. Rugo
, Olivier Trédan
, et al.
·
Breast Cancer Research and Treatment
·
34
A phase 2 study of MK-5442, a calcium-sensing receptor antagonist, in postmenopausal women with osteoporosis after long-term use of oral bisphosphonates
2015
·
F. Cosman
, N. Gilchrist
, et al.
·
Osteoporosis International
·
24
Bioavailability of Alendronate and Vitamin D3in an Alendronate/Vitamin D3Combination Tablet
2010
·
Andrew E. Denker
, Nicole Lazarus
, et al.
·
The Journal of Clinical Pharmacology
·
21
Diary of hot flashes reported upon occurrence
2014
·
James A. Simon
, Julie Chandler
, et al.
·
Menopause The Journal of The North American Menopause Society
·
18
Bioavailability and Short-Term Tolerability of Alendronate in Glucocorticoid-Treated Children
2011
·
Meranda Nakhla
, Andrew E. Denker
, et al.
·
Clinical Therapeutics
·
18
A semimechanistic model of the time-course of release of PTH into plasma following administration of the calcilytic JTT-305/MK-5442 in humans
2013
·
Antonio Cabal
, Khamir Mehta
, et al.
·
Journal of Bone and Mineral Research
·
12
PDF
Phase I-II study of ADXS31-142 alone and in combination with pembrolizumab in patients with previously treated metastatic castration-resistant prostate cancer (mCRPC): the KEYNOTE-046 trial
2015
·
Naomi B Haas
, Mark N Stein
, et al.
·
Journal for ImmunoTherapy of Cancer
·
11
PDF
Multicohort phase II KEYNOTE-059 study of pembrolizumab (MK-3475) for recurrent or metastatic gastric or gastroesophageal junction (GEJ) adenocarcinoma.
2015
·
Charles S. Fuchs
, Andrew E. Denker
, et al.
·
Journal of Clinical Oncology
·
11
Odanacatib does not influence the single dose pharmacokinetics and pharmacodynamics of warfarin.
2013
·
S Aubrey Stoch
, Rose Witter
, et al.
·
PubMed
·
10
Absence of clinically relevant drug-drug interaction between odanacatib and digoxin after concomitant administration
2013
·
S. Aubrey Stoch
, Rose Witter
, et al.
·
International Journal of Clinical Pharmacology and Therapeutics
·
9
Treatment with the cathepsin K inhibitor odanacatib in postmenopausal women with low BMD: 5year results of a phase 2 trial
2012
·
H. Resch
, N. Binkley
, et al.
·
Bone
·
9
Pharmacokinetics of digoxin in healthy subjects receiving taranabant, a novel cannabinoid-1 receptor inverse agonist
2009
·
Andrew E. Denker
, Gaetano Morelli
, et al.
·
Advances in Therapy
·
9
MK-0873, a PDE4 inhibitor, does not influence the pharmacokinetics of theophylline in healthy male volunteers
2008
·
J.D. Boot
, S.L. De Haas
, et al.
·
Pulmonary Pharmacology & Therapeutics
·
9
Mo020efficacy and Safety of the Long-acting C5 Inhibitor Ravulizumab in Patients With Postpartum Atypical Haemolytic Uraemic Syndrome
2020
·
Anja Gäckler
, Vladimir Dobronravov
, et al.
·
Nephrology Dialysis Transplantation
·
6
Show more works
View as search
Works count:
53
Citation count:
1,406
H-index:
16
I10-index:
20
Year
Topic
Type
